Publications by authors named "V A Bittner"
Heart failure (HF) is a complex and chronic condition that requires ongoing management, and in patients with adverse social determinants of health (SDOH) disease management can become challenging. Food insecurity (FI), a common adverse SDOH, can have negative consequences for those living with HF. Heart failure and SDOH also have significant impacts on mental health and well-being.
View Article and Find Full Text PDFPurpose: The Core Outcome Measures Index (COMI) is a short, multidimensional instrument translated into several languages that covers five domains recommended in the assessment of outcome in patients with low-back and neck pain. The purpose of this study was to cross-culturally adapt the COMI from English to Czech language and to test the face and construct validity and reproducibility of its results in patients with low-back and neck pain.
Methods: Participants (n = 125) were included from primary and secondary care.
This National Lipid Association (NLA) Expert Clinical Consensus provides an overview of the physiologic and clinical considerations regarding the role of apolipoprotein B (apoB) measurement to guide clinical care based on the available scientific evidence and expert opinion. ApoB represents the total concentration of atherogenic lipoprotein particles in the circulation and more accurately reflects the atherogenic burden of lipoproteins when compared to low-density lipoprotein cholesterol (LDL-C). ApoB is a validated clinical measurement that augments the information found in a standard lipoprotein lipid panel; therefore, there is clinical value in using apoB in conjunction with a standard lipoprotein lipid profile when assessing risk and managing lipid-lowering therapy (LLT).
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the relationship between triglyceride levels and the cardiovascular benefits of alirocumab compared to placebo in patients with recent acute coronary syndrome (ACS) who are on statin therapy.
- Results showed that higher baseline triglyceride levels were linked to an increased risk of major adverse cardiovascular events (MACE), whereas alirocumab significantly lowered LDL cholesterol and reduced MACE risk.
- While alirocumab led to a notable decrease in triglycerides, the reduction did not correlate with a lower risk of MACE, suggesting baseline triglyceride levels are more important for cardiovascular risk than reductions achieved through treatment.